Ignite Creation Date:
2024-05-05 @ 11:43 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00113529
Status:
COMPLETED
Last Update Posted:
2011-08-29
First Post:
2005-06-08
Brief Title:
Study Of SU011248 Plus Gefitinib Iressa In Patients With Advanced Renal Cell Carcinoma
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase 12 Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib Iressa In Patients With Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib SU011248 administered in combination with gefitinib Iressa for the treatment of patients with metastatic renal cell carcinoma Phase 1 To assess antitumor activity of the combination of gefitinib and sunitinib Phase 2
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None